Cargando…

Classical Hodgkin Lymphoma: From Past to Future—A Comprehensive Review of Pathophysiology and Therapeutic Advances

Hodgkin lymphoma, a hematological malignancy of lymphoid origin that typically arises from germinal-center B cells, has an excellent overall prognosis. However, the treatment of patients who relapse or develop resistant disease still poses a substantial clinical and research challenge, even though c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Munir, Faryal, Hardit, Viney, Sheikh, Irtiza N., AlQahtani, Shaikha, He, Jiasen, Cuglievan, Branko, Hosing, Chitra, Tewari, Priti, Khazal, Sajad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298672/ https://www.ncbi.nlm.nih.gov/pubmed/37373245 http://dx.doi.org/10.3390/ijms241210095

Ejemplares similares

Translational advances in the treatment of childhood acute lymphoblastic leukemia: narrative review of current and emerging molecular and immunotherapies
por: Munir, Faryal, et al.
Publicado: (2023)

Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant
por: Nieto, Yago, et al.
Publicado: (2023)

Post-Transplant Cyclophosphamide after Matched Sibling and Unrelated Donor Hematopoietic Stem Cell Transplantation in Pediatric Patients with Acute Myeloid Leukemia
por: Sheikh, Irtiza N., et al.
Publicado: (2022)

Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective
por: Sheikh, Irtiza N., et al.
Publicado: (2022)

The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia
por: Ragoonanan, Dristhi, et al.
Publicado: (2022)

Cardiac Relapse of Acute Lymphoblastic Leukemia Following Hematopoietic Stem Cell Transplantation: A Case Report and Review of Literature
por: Sheikh, Irtiza N., et al.
Publicado: (2021)

ATRT-19. RARE EMBRYONAL TUMORS INCLUDING EMBRYONAL TUMOR MULTILAYER ROSETTE, OUTCOME AND PATTERN OF TREATMENT FAILURE: MD ANDERSON CANCER CENTER EXPERIENCE
por: He, Jiasen, et al.
Publicado: (2023)

Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis
por: Nieto, Yago, et al.
Publicado: (2021)

LGG-24. DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR MANAGEMENT AND OUTCOME: A SINGLE CENTER EXPERIENCE
por: Munir, Faryal, et al.
Publicado: (2023)

IMMU-07. IMMUNE EFFECTOR CELL ASSOCIATED NEUROTOXICITY (ICANS) AMONG PEDIATRIC AND AYA PATIENTS: MD ANDERSON CANCER CENTER EXPERIENCE
por: Brown, Brandon, et al.
Publicado: (2020)

The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future
por: Richardson, S. E., et al.
Publicado: (2011)

A multicenter study of ICU resource utilization in pediatric, adolescent and young adult patients post CAR-T therapy
por: Ragoonanan, Dristhi, et al.
Publicado: (2022)

Transfusion reactions in pediatric and adolescent young adult haematology oncology and immune effector cell patients
por: Kohorst, Mira A., et al.
Publicado: (2020)

Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy
por: Tambaro, Francesco Paolo, et al.
Publicado: (2020)

Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies
por: Cuglievan, Branko, et al.
Publicado: (2023)

Genetics of classical Hodgkin Lymphoma
por: Schiavoni, Gianluca, et al.
Publicado: (2018)

Hematopoietic stem cell transplantation for the management of follicular lymphoma
por: Hosing, Chitra
Publicado: (2010)

Central nervous system Langerhans cell histiocytosis and neurodegenerative syndrome responding to MEK inhibition
por: Wahba, Andrew, et al.
Publicado: (2021)

Immune Effector Cell Associated Neurotoxicity (ICANS) in Pediatric and Young Adult Patients Following Chimeric Antigen Receptor (CAR) T-Cell Therapy: Can We Optimize Early Diagnosis?
por: Brown, Brandon Douglas, et al.
Publicado: (2021)

Remdesivir Therapy for COVID-19 Pneumonia in a Pediatric Bone Marrow Transplant Patient
por: Hardit, Viney, et al.
Publicado: (2021)

The molecular mechanisms of classic Hodgkin's lymphoma.
por: Felberbaum, Rachael S.
Publicado: (2005)

Immunological Deregulation in Classic Hodgkin Lymphoma
por: Romano, Alessandra, et al.
Publicado: (2014)

Controversies in the Treatment of Classical Hodgkin Lymphoma
por: Eichenauer, Dennis A., et al.
Publicado: (2018)

The Grey Zones of Classic Hodgkin Lymphoma
por: Bosch-Schips, Jan, et al.
Publicado: (2022)

The real risk of secondary non-Hodgkin lymphoma following classical Hodgkin lymphoma
por: Dogan, Ahmet
Publicado: (2022)

Bob-1 is expressed in classic Hodgkin lymphoma
por: Abd El All, Howayda S
Publicado: (2007)

Resources-Stratified Guidelines for Classical Hodgkin Lymphoma
por: Relecom, Allan, et al.
Publicado: (2020)

MicroRNA signature in classical Hodgkin lymphoma
por: Paczkowska, Julia, et al.
Publicado: (2021)

Composite follicular lymphoma and classic Hodgkin lymphoma
por: Kim, Han-Na, et al.
Publicado: (2022)

Bone marrow involvement by classic Hodgkin lymphoma
por: Barouqa, Mohammad, et al.
Publicado: (2022)

Aberrant synaptophysin expression in classic Hodgkin lymphoma
por: Im, Soyoung, et al.
Publicado: (2022)

Current directions in the treatment of classical Hodgkin lymphoma
por: Keller, Frank G., et al.
Publicado: (2023)

CAR-T Cell Therapy for Classical Hodgkin Lymphoma
por: Katsin, Mikalai, et al.
Publicado: (2023)

Hemophagocytic Lymphohistiocytosis in a Patient with Classical Hodgkin Lymphoma
por: Hyun, G., et al.
Publicado: (2016)

The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma
por: Meti, Nicholas, et al.
Publicado: (2018)

Combined linkage and association analysis of classical Hodgkin lymphoma
por: Lawrie, Alastair, et al.
Publicado: (2018)

Mucocutaneous Paraneoplastic Syndrome Secondary to Classical Hodgkin’s Lymphoma
por: Jurkovic, Jenna, et al.
Publicado: (2019)

Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
por: Voorhees, Timothy J, et al.
Publicado: (2020)

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai, Catherine, et al.
Publicado: (2019)

Classical Hodgkin’s Lymphoma in the Era of Immune Checkpoint Inhibition
por: De Re, Valli, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_c0gvo71tvtcqvqie7ta3oabpua